A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : ER/PR

Search Conditions:
Search Keyword : ER/PR
Search Method : Exact match.
Research Area:

Abbreviation: ER/PR
Appearance Frequency: 175 time(s)
Long forms: 8

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
estrogen receptor/progesterone receptor
(162 times)
(84 times)
HER2 (21 times)
OS (14 times)
IHC (11 times)
1985 Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastasis on survival of breast cancer patients.
(7 times)
(3 times)
IHC (2 times)
pCR (2 times)
ALNI (1 time)
1994 An approach to preliminary studies of interlaboratory comparative results for estrogen and progesterone receptors.
E or P receptors
(1 time)
(1 time)
SERT (2 times)
LC (1 time)
NET (1 time)
1997 Lack of ovarian steroid hormone regulation of norepinephrine transporter mRNA expression in the non-human primate locus coeruleus.
elastosis, lymph node metastasis and Oestrogen and Progesterone Receptor
(1 time)
(1 time)
AgNORs (2 times)
1996 Prognostic value of argyrophylic nucleolar organiser regions (AgNORs) in breast lesions.
epidermal growth factor receptor, oestrogen and progesterone receptor
(1 time)
(1 time)
CAIX (1 time)
GLUT1 (1 time)
MVD (1 time)
2010 A profile of prognostic and molecular factors in European and Maori breast cancer patients.
especially for steroid hormone receptors
(1 time)
(1 time)
GCDFP (1 time)
2014 Breast as an unusual site of metastasis- series of 3 cases and review of literature.
expression of Oestrogen Receptors/Progesterone Receptors
(1 time)
Clinical Medicine
(1 time)
FISH (1 time)
IHC (1 time)
2017 HER2/neu Testing In 432 Consecutive Breast Cancer Cases using FISH and IHC - A Comparative Study.
expression was compared with hormone receptor
(1 time)
(1 time)
--- 2005 The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course.